These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 24816427)

  • 1. Generation of anti-idiotype scFv for pharmacokinetic measurement in lymphoma patients treated with chimera anti-CD22 antibody SM03.
    Zhao Q; Wong PF; Lee SS; Leung SO; Cheung WT; Wang JZ
    PLoS One; 2014; 9(5):e96697. PubMed ID: 24816427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogate target cells expressing surface anti-idiotype antibody for the clinical evaluation of an internalizing CD22-specific antibody.
    Leung SO; Gao K; Wang GY; Cheung BK; Lee KY; Zhao Q; Cheung WT; Wang JZ
    MAbs; 2015; 7(1):66-76. PubMed ID: 25427174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and evaluation of the specificity of a rat monoclonal anti-idiotype antibody, WN, to an anti-B-cell lymphoma monoclonal antibody, LL2.
    Losman MJ; Leung SO; Shih LB; Shevitz J; Shukla R; Haraga L; Goldenberg DM; Hansen HJ
    Cancer Res; 1995 Dec; 55(23 Suppl):5978s-5982s. PubMed ID: 7493380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific Targeting of Lymphoma Cells Using Semisynthetic Anti-Idiotype Shark Antibodies.
    Macarrón Palacios A; Grzeschik J; Deweid L; Krah S; Zielonka S; Rösner T; Peipp M; Valerius T; Kolmar H
    Front Immunol; 2020; 11():560244. PubMed ID: 33324393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Pharmacodynamics and Preliminary Observations for Clinical Activity and Safety of Multiple Doses of Human Mouse Chimeric Anti-CD22 Monoclonal Antibody (SM03) in Chinese Patients with Systemic Lupus Erythematosus.
    Zhao Q; Chen X; Li J; Jiang J; Li M; Zhong W; Li Z; Leung SO; Zhang F; Hu P
    Clin Drug Investig; 2016 Nov; 36(11):889-902. PubMed ID: 27424629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific targeting to B cells by lipid-based nanoparticles conjugated with a novel CD22-ScFv.
    Loomis K; Smith B; Feng Y; Garg H; Yavlovich A; Campbell-Massa R; Dimitrov DS; Blumenthal R; Xiao X; Puri A
    Exp Mol Pathol; 2010 Apr; 88(2):238-49. PubMed ID: 20122924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation of high-affinity, neutralizing anti-idiotype antibodies by phage and ribosome display for application in immunogenicity and pharmacokinetic analyses.
    Chin SE; Ferraro F; Groves M; Liang M; Vaughan TJ; Dobson CL
    J Immunol Methods; 2015 Jan; 416():49-58. PubMed ID: 25449532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production and characterization of an anti-idiotypic single chain Fv that recognizes an anti-DNA antibody.
    Kwon MH; Lee MS; Kim KH; Park S; Shin HJ; Jang YJ; Kim HI
    Immunol Invest; 2002; 31(3-4):205-18. PubMed ID: 12472180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High efficient expression of a functional humanized single-chain variable fragment (scFv) antibody against CD22 in Pichia pastoris.
    Zarei N; Vaziri B; Shokrgozar MA; Mahdian R; Fazel R; Khalaj V
    Appl Microbiol Biotechnol; 2014 Dec; 98(24):10023-39. PubMed ID: 25239038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and tolerability of human mouse chimeric anti-CD22 monoclonal antibody in Chinese patients with CD22-positive non-Hodgkin lymphoma.
    Li S; Zhang D; Sun J; Li Z; Deng L; Zou B; Zhan J; Jiang W
    MAbs; 2012; 4(2):256-66. PubMed ID: 22453099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gangliosides, Ab1 and Ab2 antibodies III. The idiotype of anti-ganglioside mAb P3 is immunogenic in a T cell-dependent manner.
    López-Requena A; Bestagno M; Mateo de Acosta C; Cesco-Gaspere M; Vázquez AM; Pérez R; Burrone OR
    Mol Immunol; 2007 Apr; 44(11):2915-22. PubMed ID: 17316805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open-label, multiple-dose study to assess the preliminary pharmacokinetics, pharmacodynamics, clinical activity, and safety of human mouse chimeric anti-CD22 monoclonal antibody (SM03) in patients with rheumatoid arthritis.
    Zhao Q; Chen X; Jiang J; Li J; Zhong W; Han H; Li Z; Leung SO; Zhang F; Hu P
    Int J Clin Pharmacol Ther; 2021 Nov; 59(11):691-704. PubMed ID: 34423769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SM03, an Anti-CD22 Antibody, Converts
    Wong KL; Li Z; Ma F; Wang D; Song N; Chong CH; Luk KK; Leung SO
    J Immunol; 2022 Jun; 208(12):2726-2737. PubMed ID: 35688465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies.
    Torchia J; Weiskopf K; Levy R
    Proc Natl Acad Sci U S A; 2016 May; 113(19):5376-81. PubMed ID: 27114517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bacterial expression and characterization of an anti-CD22 single-chain antibody fragment.
    Mikiewicz D; Łukasiewicz N; Zieliński M; Cecuda-Adamczewska V; Bierczyńska-Krzysik A; Romanik-Chruścielewska A; Kęsik-Brodacka M
    Protein Expr Purif; 2020 Jun; 170():105594. PubMed ID: 32032771
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination with human anti-trastuzumab anti-idiotype scFv reverses HER2 immunological tolerance and induces tumor immunity in MMTV.f.huHER2(Fo5) mice.
    Ladjemi MZ; Chardes T; Corgnac S; Garambois V; Morisseau S; Robert B; Bascoul-Mollevi C; Ait Arsa I; Jacot W; Pouget JP; Pelegrin A; Navarro-Teulon I
    Breast Cancer Res; 2011 Feb; 13(1):R17. PubMed ID: 21294885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen.
    Foon KA; Oseroff AR; Vaickus L; Greenberg SJ; Russell D; Bernstein Z; Pincus S; Köhler H; Seon BK; Tahaoglu E
    Clin Cancer Res; 1995 Nov; 1(11):1285-94. PubMed ID: 9815923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD20 single chain variable antibody fragment-apolipoprotein A-I chimera containing nanodisks promote targeted bioactive agent delivery to CD20-positive lymphomas.
    Crosby NM; Ghosh M; Su B; Beckstead JA; Kamei A; Simonsen JB; Luo B; Gordon LI; Forte TM; Ryan RO
    Biochem Cell Biol; 2015 Aug; 93(4):343-50. PubMed ID: 25994015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Production and characterization of a human monoclonal anti-idiotype to anti-ribosomal P antibodies.
    Zhang W; Reichlin M
    Clin Immunol; 2005 Feb; 114(2):130-6. PubMed ID: 15639646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of anti-idiotype antibodies for application in clinical immunotherapy laboratory analyses.
    Liu Z; Panousis C; Smyth FE; Murphy R; Wirth V; Cartwright G; Johns TG; Scott AM
    Hybrid Hybridomics; 2003 Aug; 22(4):219-28. PubMed ID: 14511567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.